Sunday, July 12, 2009
Chris Reidy of the Boston Globe wrote that that Alnylam will contribute more than 1,500 issued or pending patents on its RNA interference (RNAi) technology patent estate to the patent pool established by GSK earlier this year for neglected tropical diseases (NTD).
0 Comments:
Post a Comment
<< Home